Trial Profile
Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib in First-line Metastatic Pancreatic Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Nov 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 01 Oct 2021 Primary endpoint has not been met. (progression-free survival (PFS), as per Results published in the Oncologist
- 01 Oct 2021 Results published in the Oncologist
- 03 Dec 2020 Status changed from active, no longer recruiting to completed.